To evaluate the presence of antibodies to conformation-intact myelin oligodendrocyte glycoprotein (MOG) in a subgroup of adult patients with clinically definite multiple sclerosis (MS) preselected for a specific clinical phenotype including severe spinal cord, optic nerve, and brainstem involvement.
Antibodies to MOG were investigated using a cell-based assay in 3 groups of patients: 104 preselected patients with MS (group 1), 55 age- and sex-matched, otherwise unselected patients with MS (group 2), and in 22 brain-biopsied patients with demyelinating diseases of the CNS (n = 19 with MS), 4 of whom classified as MS type II (group 3). Recognized epitopes were identified with mutated variants of MOG.
Antibodies to MOG were found in about 5% (5/104) of preselected adult patients with MS. In contrast, in groups 2 and 3, none of the patients tested positive for MOG antibodies. Patients with MS with antibodies to MOG predominantly manifested with concomitant severe brainstem and spinal cord involvement and had a severe disease course with high relapse rates and failure to several disease-modifying therapies. Three of them had been treated with plasma exchange with a favorable response. All anti-MOG–positive patients with MS showed typical MS lesions on brain MRI. Longitudinal analysis up to 9 years revealed fluctuations and reappearance of anti-MOG reactivity. Epitope mapping indicated interindividual heterogeneity, yet intraindividual stability of the antibody response.
(1) Philips Scientific Advisory Board (commercial entity) (2) Bracco Editorial Board (commercial entity) (3) Springer Medical Publisher (comercial entity)
(1) Siemens, speaker honoraria, travel expenses (2) Philips, speaker honoraria, travel expenses (3) Bracco, travel expenses (4) Bayer Schering, speaker honoraria, travel expenses
(1) Journal of the American College of Radiology, Associate International Editor, since 2010 (2) European Radiology, since 2014
(1) Paediatrische Neuroraiologie, Springer Medical Publisher, 2005 (2) Aerztliches Qualitaetsmanagement, Springer Medical Publisher, 2009, 2012 (3) Radiologie Trainer 3 Baende, Thieme Medical Publisher, 2005, 2012
(1) Guerbet (2) Eli Lily (3) Bracco (4) Merck Serono (5) Novartis (6) Bayer Schering Institutional support
(1) Bundesministerium fuer Forschung und Technik (2) Deutsche Forschungsgemeinschaft (3) National Institutes of Health
(1) Bayerische Forschungsstiftung Stock/Stock Options, Medical Equipment & Materials: (1) Siemens healthcare, stock options held by husband
1)commercial: speaker honoraria, travel grants from BiogenIdec, Bayer Healthcare, TEVA, Serono, Novartis, Genzyme
grants from German Ministry for Education and Research (BMBF, ??German Competence Network Multiple Sclerosis?? (KKNMS), Pattern MS/NMO);
I serve on the advisory board of Genzyme, Novartis, Biogenand Teva Pharma.
I received honoraria for oral presentations from Teva,Sanofi, Genzyme, Novartis, Merck-Serono, Biogen and Bayer in the last 2 years.
I am editorial board member of Acta neuropathologica, Therapeutic Advances in Neurological disorders, Multiple Sclerosis International and Neuropathology and Applied Neurobiology
German Research foundation (DFG SFB TR43): The brain as a target of inflammatory processes, 2008-2015 German ministry for science and education: Competence network multiple sclerosis, 2010-2018
Served on Scientific Advisory boards for Novartis; Biogen- Idec; Bayer-Schering; Merck-Serono; Sanofi-Aventis; Teva; Served on data safety monitoring boards for Novartis; Merck Serono (since 2007); CSL Behring; Medday; Actelion
Received funding for trips from Novartis; Biogen-Idec; Bayer-Schering; Merck-Serono; Sanofi- Aventis; Teva; Genzyme
Serve as editorial board member of Neurology (currently); Brain; Clinical and Experimental Immunology; Deutsche Medizinische Wochenschrift; Expert Opinion on Biological Therapy; Journal of Neuroimmunology; Multiple Sclerosis; Nervenarzt; Practical Neurology; Seminars in Immunopathology; Therapeutic Advances in Neurological Disorders
Receive consulting fees from Novartis; Biogen-Idec; Bayer- Schering; Merck-Serono; Sanofi-Aventis; Teva; Genzyme; Medday; Actelion
Received grant support from Novartis (2008 to present); Biogen-Idec (2005-2009); Bayer-Schering (2001-2006); Teva (1999-2007)
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.